Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
441-460 of 998 trials

Melanoma Treatment: Nivolumab with Isolated Limb Perfusion

We are studying whether combining nivolumab with isolated limb perfusion helps patients with in-transit melanoma metastases achieve better treatment responses. This trial will also look at safety and quality of life.

In-transit Metastasis of Malignant Melanoma1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteDermatologyOncology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Relapsing Multiple Sclerosis: Remibrutinib vs. Teriflunomide

We are studying whether remibrutinib is more effective than teriflunomide in reducing relapses for individuals with relapsing multiple sclerosis. The trial also examines the safety and impact of both treatments on daily life.

Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteNeurology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Schizophrenia Spectrum Disorders: Oxytocin Treatment Study

We are investigating whether intranasal oxytocin can enhance social skills and functioning in individuals with schizophrenia spectrum disorders. This study compares oxytocin to a placebo alongside standard psychosocial treatment.

Schizophrenia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Type 1 Diabetes: Sotagliflozin for Kidney Health

We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.

Type 1 Diabetes with Kidney Complications6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInternal MedicineNephrology

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineOphthalmology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Ulcerative Colitis: Oral Mesalazine Treatment

We are studying an oral medication for people with mild to moderate ulcerative colitis to see if it helps induce remission of symptoms. The trial will assess various measures of improvement after treatment.

Ulcerative Colitis3-6 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Bipolar Disorder Type II: Lithium vs. Lamotrigine Study

We are comparing the effects of lithium and lamotrigine on mood stabilization in people with bipolar disorder type II. The goal is to see which treatment may better reduce symptoms and improve daily functioning.

Bipolar Disorder, Type II1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics